Apply to trial NCT05498792

A few quick questions so the study team can decide if you might be a fit.

RecruitingEarly Phase 1Drug trial

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced and metastatic melanoma who are candidates for immune checkpoint blockade and have tumors accessible for serial biopsies.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening